Featured Research

from universities, journals, and other organizations

Three-drug Chemotherapy Combination Increases Organ Preservation In Patients With Larynx Cancer

Date:
April 1, 2009
Source:
Journal of the National Cancer Institute
Summary:
Patients with larynx cancer who received a three-drug combination of docetaxel, cisplatin and 5-fluorouracil during induction chemotherapy were more likely to retain larynx function than were patients treated with cisplatin and 5-fluoruracil alone, according to data from a randomized controlled trial.

Patients with larynx cancer who received a three-drug combination of docetaxel, cisplatin and 5-fluorouracil (TPF) during induction chemotherapy were more likely to retain larynx function than were patients treated with cisplatin and 5-fluoruracil (PF) alone, according to data from a randomized controlled trial in the March 24 online issue of the Journal of the National Cancer Institute.

Patients with locally advanced larynx and hypopharynx cancer are treated frequently with PF chemotherapy followed by radiation as an alternative to surgical removal of the larynx. Recent trials have suggested that adding docetaxel to PF might further improve patient outcomes.

To test this possibility, Gilles Calais, M.D., of the Centre Hospitalier Régional et Universitaire de Tours in France, and colleagues enrolled 213 patients with advanced larynx and hypopharynx cancer in a randomized controlled trial. Patients received induction chemotherapy with either TPF or PF. Those who responded to chemotherapy underwent subsequent radiation therapy, while those who did not respond were treated with surgery.

With a median follow-up time of 3 years, the estimated larynx preservation rate was 70.3 percent in the TPF-treated patients and 57.5 percent in the PF-treated patients. Overall, 80.0 percent of patients in the TPF group responded to therapy, compared with 59.2 percent in the PF group. Patients treated with TPF had more severe infections than those treated with PF.

The authors conclude that the treatment regimen with docetaxel was superior for patients with locally advanced cancers of the larynx and hypopharynx and that more of these patients could avoid total laryngectomy. However, they caution that "Because we proposed treatment to a select popula¬tion of patients with only larynx and hypopharynx cancer and this trial was especially designed for organ preservation, we cannot gen¬eralize the findings to all locally advanced head and neck cancers."


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Yoann Pointreau, Pascal Garaud, Sophie Chapet, Christian Sire, Claude Tuchais, Jacques Tortochaux, Sandrine Faivre, Stephane Guerrif, Marc Alfonsi, and Gilles Calais. Randomized Trial of Induction Chemotherapy with Cisplatin and 5-fluorouracil with or Without Docetaxel for Larynx Preservation. J Natl Cancer Inst, 2009; 101: 498-506 DOI: 10.1093/jnci/djp007

Cite This Page:

Journal of the National Cancer Institute. "Three-drug Chemotherapy Combination Increases Organ Preservation In Patients With Larynx Cancer." ScienceDaily. ScienceDaily, 1 April 2009. <www.sciencedaily.com/releases/2009/03/090324171428.htm>.
Journal of the National Cancer Institute. (2009, April 1). Three-drug Chemotherapy Combination Increases Organ Preservation In Patients With Larynx Cancer. ScienceDaily. Retrieved August 1, 2014 from www.sciencedaily.com/releases/2009/03/090324171428.htm
Journal of the National Cancer Institute. "Three-drug Chemotherapy Combination Increases Organ Preservation In Patients With Larynx Cancer." ScienceDaily. www.sciencedaily.com/releases/2009/03/090324171428.htm (accessed August 1, 2014).

Share This




More Health & Medicine News

Friday, August 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) — The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Despite Health Questions, E-Cigs Are Beneficial: Study

Despite Health Questions, E-Cigs Are Beneficial: Study

Newsy (July 31, 2014) — Citing 81 previous studies, new research out of London suggests the benefits of smoking e-cigarettes instead of regular ones outweighs the risks. Video provided by Newsy
Powered by NewsLook.com
Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) — Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins